2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14608S7
    L-Glutamic acid-d5 2784-50-1 99.84%
    L-Glutamic acid-d5 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-d5
  • HY-W014901
    Bisphenol F 620-92-8 99.93%
    Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260).
    Bisphenol F
  • HY-W040129
    Chromomycin A3 7059-24-7 ≥99.0%
    Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe.
    Chromomycin A3
  • HY-12199
    Pitolisant 362665-56-3 99.73%
    Pitolisant is a potent and selective nonimidazole inverse agonist at the recombinant human histamine H3 receptor (Ki=0.16 nM).
    Pitolisant
  • HY-B0071
    Granisetron 109889-09-0 99.88%
    Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
    Granisetron
  • HY-P1389
    Neuropeptide S (human) 412938-67-1 99.90%
    Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research.
    Neuropeptide S (human)
  • HY-P1363F3
    5-FAM-β-Amyloid (1-42), human Tris
    5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).
    5-FAM-β-Amyloid (1-42), human Tris
  • HY-17566
    Capreomycin sulfate 1405-37-4 99.52%
    Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease.
    Capreomycin sulfate
  • HY-100234
    DREADD agonist 21 56296-18-5 99.46%
    DREADD agonist 21 is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC50=1.7 nM).
    DREADD agonist 21
  • HY-13237
    GSK2578215A 1285515-21-0 99.82%
    GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC50s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.
    GSK2578215A
  • HY-18941
    Eglumegad 176199-48-7 ≥98.0%
    Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 nM and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
    Eglumegad
  • HY-A0079
    Tetracaine 94-24-6 99.87%
    Tetracaine (Amethocaine) is a sodium channel inhibitor and ryanodine receptor (RyR) inhibitor. Tetracaine blocks sodium conduction across nerve cell membranes, preventing rapid sodium ion influx and depolarization. Tetracaine exhibits biphasic effects on spontaneous sarcoplasmic reticulum Ca2+ release in Ca2+-overloaded ventricular myocytes, and increases sarcoplasmic reticulum Ca2+ load. Tetracaine can be used in research related to eye diseases.
    Tetracaine
  • HY-108039
    Bezisterim 1001100-69-1
    Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial NF-κB inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis. Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bezisterim
  • HY-109123
    Soticlestat 1429505-03-2 99.83%
    Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research.
    Soticlestat
  • HY-109171
    Elinzanetant 929046-33-3 99.82%
    Elinzanetant is an orally active and selective NK-1 and NK-3 receptor antagonist. Elinzanetant alleviates menopause-associated vasomotor symptoms, including hot flashes and night sweats. Elinzanetant reduces estradiol and progesterone levels. Elinzanetant can be used for the research of moderate to severe vasomotor and sleep disorders associated with menopause.
    Elinzanetant
  • HY-13781
    Pemetrexed disodium hemipenta hydrate 357166-30-4 99.78%
    Pemetrexed (LY231514) disodium hemipenta hydrate is a CNS-penetrant antifolate, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively.
    Pemetrexed disodium hemipenta hydrate
  • HY-17474
    Parecoxib 198470-84-7 99.29%
    Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib
  • HY-42068
    (-)-Aspartic acid 1783-96-6
    (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
    (-)-Aspartic acid
  • HY-B1078
    Cefazolin sodium 27164-46-1 98.45%
    Cefazolin sodium is a first-generation cephalosporin antibiotic and can be used in varieties of bacterial infections research. Cefazolin sodium has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD).
    Cefazolin sodium
  • HY-B1122
    L-Cycloserine 339-72-0 99.41%
    L-Cycloserine ((S)-4-Amino-3-isoxazolidone) is an oral inhibitor of the enzyme gamma-aminobutyric acid (GABA) transaminase (GABA-t) and branched-chain transaminases in Mycobacterium tuberculosis. L-Cycloserine has anticonvulsant properties and inhibits the synthesis of neurotensin in mouse brains.
    L-Cycloserine
Cat. No. Product Name / Synonyms Application Reactivity